The U.S. Food and Drug Administration has approved the first drug specifically developed for severe depression after childbirth. The agency on Tuesday approved Sage Therapeutics’ Zulresso, an IV drug given over two and a half days. Sage said Zulresso will cost $ 34,000 without insurance, plus costs for staying in a hospital or infusion center.… Read More »
The Food and Drug Administration on Tuesday issued its first-ever approval of a postpartum depression therapy, offering a new treatment option for the roughly one in nine women who experience this kind of disorder. The question remains, however, of how accessible that option will end up being for patients. Branded as Zulresso, the therapy supplies… Read More »
Print this page March 5, 2019 — The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression). Because of the risk of serious adverse outcomes resulting… Read More »
February 01, 2019 Share this content: Participants who reported chronic headaches were found likely to develop migraines. Increased headache day frequency, acute medication overuse and/or high-frequency use, and depression were the most strongly identified risk factors identified for the new onset of chronic migraine (CM)/transformed migraine (TM), chronic daily headache (CDH), or related chronic headache… Read More »
Women going through menopause may have fewer symptoms of depression when they get treatment for insomnia than when they don’t, a recent experiment suggests. Researchers recruited 117 menopausal women with insomnia for the study and randomly assigned them to three groups. One group received cognitive behavior therapy (CBT). Another group received a component of CBT… Read More »